Long-term quantitative hepatitis B surface antigen (HBsAg) trajectories in persons with and without HBsAg loss on tenofovir-containing antiretroviral therapy.

Lorin BegréAnders BoydLuisa Salazar-VizcayaFranziska Suter-RinikerCharles BéguelinJürgen K RockstrohHuldrych F GünthardAlexandra CalmyMatthias CavassiniMarcel StöcklePatrick SchmidEnos BernasconiMassimo LevreroFabien ZoulimGilles WandelerAndri Rauchnull null

Published in: HIV medicine (2023)

Most persons with HIV who experienced HBsAg loss had an early decline in qHBsAg levels, with diverse trajectories during long-term tenofovir therapy. In persons without HBsAg loss, qHBsAg levels remained remarkably stable over time.

Keyphrases

antiretroviral therapy
hepatitis b virus
hiv infected
hiv positive
human immunodeficiency virus
hiv infected patients
hiv aids
depressive symptoms
hepatitis c virus
high resolution
stem cells
replacement therapy
smoking cessation